Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21915057 | 1.00 | C3AR1 (0.34) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL24490420 | 1.00 | C3AR1 (0.34) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL23106105 | 0.90 | C3AR1 (0.34) | C3AR1FURINRENSIRT5SIRT6 | |
| SCHEMBL23393940 | 0.90 | SIRT5 (0.39) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL18818915 | 0.90 | REN (0.34) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL23106038 | 0.89 | NPY4R (0.39) | FURIN | |
| SCHEMBL20795891 | 0.89 | FURIN (0.36) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL23736705 | 0.89 | FURIN (0.36) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL21103418 | 0.89 | SIRT5 (0.36) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL1711524 | 0.89 | C3AR1 (0.44) | C3AR1FURINPOLBKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173074-A2 | IMMUNOSTIMULANT-CYTOTOXIC CONJUGATE COMPOSITION AND METHODS FOR CANCER TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-14 | — | — | WO | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-3892305-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | Sutro Biopharma, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS ACQUISITION CORPORATION | 2021-03-18 | — | — | US | disclosed |
| US-20200405813-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200207859-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | SUTRO BIOPHARMA, INC. | 2020-07-02 | — | — | US | disclosed |
| US-20200147229-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | CYP17A1, HSD17B7, SHBG | C3AR1 2114/4885FURIN 3399/4885LMNA 1536/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | C3AR1 104/4885FURIN 3721/4885LMNA 4861/4885 |
| US-20200207859-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | CD74, CD99, CD2 | C3AR1 1110/4885FURIN 3698/4885LMNA 1666/4885 |
| US-20200405813-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | C3AR1 154/4885FURIN 3545/4885LMNA 4795/4885 |
| US-20200147229-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | C3AR1 217/4885FURIN 2107/4885LMNA 3893/4885 |
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | PAICS, ANXA3, APOB | C3AR1 452/4885FURIN 1194/4885LMNA 438/4885 |
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | C3AR1 2114/4885FURIN 3399/4885LMNA 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.